Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis

Journal of Thoracic Disease

Volumn 7, Issue 4, 2015, Pages 603-615

  Zhang, Xin ^a,b   Falagas, Matthew E ^c   Vardakas, Konstantinos Z ^c   Wang, Rui ^a   Qin, Rong ^a   Wang, Jin ^c   Liu, Youning ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b Outpatient Department of Navy Headquarters ^*  (China)

^c ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

Author keywords

Extensively drug resistant TB (XDR TB); Linezolid; Meta analysis; Multidrug resistant tuberculosis (MDR TB); Treatment

Indexed keywords

LINEZOLID;

ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; META ANALYSIS; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NEUROLOGIC DISEASE; OPTIC NEURITIS; PANCYTOPENIA; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SPUTUM CULTURE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

EID: 84928530557     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2015.03.10     Document Type: Article

References (47)

1. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012;380:1406-17.
2. World Health Organization. Global tuberculosis report 2013. World Health Organization, 2013.
3. Dye C, Glaziou P, Floyd K, et al. Prospects for tuberculosis elimination. Annu Rev Public Health 2013;34:271-86.
4. Yang C, Lei H, Wang D, et al. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China. Jpn J Infect Dis 2012;65:240-2.
5. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42:169-79.
6. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68.
7. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28.
8. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014;43:554-65.
9. Field SK, Fisher D, Jarand JM, et al. New treatment options for multidrug-resistant tuberculosis. Ther Adv Respir Dis 2012;6:255-68.
10. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007;8:2381-400.
11. Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003;47:416-7.
12. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 1999;8:1195-202.
13. Zurenko GE, Gibson JK, Shinabarger DL, et al. Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol 2001;1:470-6.
14. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 Update. World Health Organization 2011.
15. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:e1001300.
16. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-5.
17. Nam HS, Koh WJ, Kwon OJ, et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009;33:92-3.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
20. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
23. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
24. Baschnagel AM, Yadav S, Marina O, et al. Toxicities and costs of placing prophylactic and reactive percutaneous gastrostomy tubes in patients with locally advanced head and neck cancers treated with chemoradiotherapy. Head Neck 2014;36:1155-61.
25. Xu HB, Jiang RH, Li L, et al. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis 2012;16:358-63.
26. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006;52:92-6.
27. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011;38:730-3.
28. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. Eur Respir J 2010;35:936-8; author reply 938-40.
29. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012;39:956-62.
30. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010;50:49-55.
31. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4.
32. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009;34:387-93.
33. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18.
34. Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012;67:1503-7.
35. Fortún J, Martín-Dávila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-5.
36. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012;39:770-2.
37. Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010;65:775-83.
38. Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2012;67:473-7.
39. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447-54.
40. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430-42.
41. Abena PA, Mathieux VG, Scheiff JM, et al. Linezolid and reversible myelosuppression. JAMA 2001;286:1973; author reply 1974.
42. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31.
43. Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006;66:595-8.
44. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013;42:785-801.
45. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014;43:1410-20.
46. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013;42:1449-53.
47. Alffenaar JW, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010;49:559-65.